Abstract
Objective: To investigate the efficacy of somatostatin for the treatment of severe acute pancreatitis. Design: Prospective, randomized and unblinded study. Setting: A general intensive care unit (ICU) in a university hospital. Patients: 50 patients with severe acute pancreatitis. Interventions: All patients received the conventional treatment for this clinical condition. The study group received, in addition, somatostatin over a 10-day period. Measurements and results: We evaluated age, gender, etiology of the pancreatitis, severity of the illness, complications, length of hospitalization, and mortality in the ICU. The patients were classified as severe (Acute Physiology and Chronic Health Evaluation II score, Ranson's criteria, and computed tomography Balthazar classification). Biliary lithiasis was the most common etiologic factor (63.6 % in the control group, 37.5 % in study group; NS). The study group required fewer overall surgical interventions than the control group (45.8 vs 86.4 %; p = 0.005). Late surgical procedures related to the evolution of pancreatic necrosis were more common in the controls (63.6 vs 37.5 %; p = 0.07). No differences in length of stay in hospital or mortality in the ICU were observed. Conclusion: The only advantage of somatostatin administration in the patients studied was a slight reduction in the need for surgery due to local complications.
Similar content being viewed by others
Author information
Authors and Affiliations
Additional information
Received: 4 September 1995 Accepted: 6 November 1997
Rights and permissions
About this article
Cite this article
Planas, M., Pérez, A., Iglesia, R. et al. Severe acute pancreatitis: treatment with somatostatin. Intensive Care Med 24, 37–39 (1998). https://doi.org/10.1007/s001340050512
Published:
Issue Date:
DOI: https://doi.org/10.1007/s001340050512